PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1454745
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1454745
Cervical Cancer Diagnostics Market Size - By Diagnostic Methods, Age Group, End-use & Forecast, 2024-2032
Cervical Cancer Diagnostics Market size is estimated to expand at over 5.3% CAGR from 2024 to 2032, on account of the increasing awareness about the importance of early detection and screening programs for cervical cancer. Rising developments in diagnostic techniques like HPV testing and liquid-based cytology are improving the accuracy and efficiency of cervical cancer diagnosis.
The rising incidences of cervical cancer globally, especially in developing regions, are increasing the demand for diagnostics. As per the American Cancer Society, in 2024, 13,820 new cases of invasive cervical cancer will be diagnosed in the U.S. Several governments are also launching initiatives and healthcare campaigns to promote cervical cancer screening and prevention.
In September 2023, scientists at the International Agency for Research on Cancer (IARC) and its partners launched the EASTER project, aimed at validating new technologies for cervical cancer screening and diagnosis. The launch of such projects to develop new technologies for cervical cancer diagnosis will provide impetus for the market development.
The cervical cancer diagnostics industry is bifurcated into diagnostic method, age group, end-use, and region.
Based on diagnostic method, the market value from the HPV DNA tests is anticipated to rise at 5.6% CAGR up to 2032, due to the high adoption for cervical cancer diagnosis. These tests offer high sensitivity and specificity in detecting human papillomavirus (HPV) infections, a leading cause of cervical cancer. HPV DNA tests also enable early detection and intervention for improved patient outcomes, further driving increasing utilization in cervical cancer screening programs worldwide.
In terms of end-use, the diagnostic imaging centers segment is estimated to accumulate sizeable share of the cervical cancer diagnostics market, depicting 4.9% CAGR from 2024 to2032. This is owing to the increasing awareness about the importance of regular cervical cancer screening. Of late, there has been high availability of advanced diagnostic imaging technologies in dedicated centers. These centers provide specialized services for cervical cancer detection for offering accurate and timely diagnosis through techniques such as colposcopy, MRI, and ultrasound, contributing to improved patient outcomes.
Regionally, the Asia Pacific cervical cancer diagnostics market size will depict 5.6% growth rate from 2024 to 2032, owing to the rising healthcare expenditure, increasing awareness campaigns, and rollout of government initiatives to improve women health. Rapid advancements in healthcare infrastructure in emerging economies like China and India, along with the growing adoption of screening programs will fuel the regional industry expansion.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Base estimates & calculations
- 1.3 Data collection
- 1.4 Forecast calculations
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of cervical cancer globally
- 3.2.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness
- 3.2.1.3 Rising incidence of HPV Infections
- 3.2.1.4 Advancements in diagnostic technologies
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Limited access to healthcare services
- 3.2.2.2 Social stigma and cultural barriers
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Technological landscape
- 3.5 Regulatory landscape
- 3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive analysis of major market players
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Diagnostic Methods, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Pap smear tests
- 5.3 HPV DNA tests
- 5.4 Colposcopy
- 5.5 Biopsy and endocervical curettage
- 5.6 Other diagnostic methods
Chapter 6 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 20-40 years
- 6.3 Above 40 years
Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Diagnostic laboratories
- 7.4 Diagnostic imaging centers
- 7.5 Cancer research institutes
- 7.6 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Abbott Laboratories
- 9.2 Arbor Vita Corporation
- 9.3 Becton, Dickinson and Company (BD)
- 9.4 Danaher Corporation
- 9.5 F. Hoffmann-La Roche Ltd
- 9.6 Fujirebio Diagnostics, Inc.
- 9.7 Hologic, Inc.
- 9.8 QIAGEN
- 9.9 Seegene Inc
- 9.10 Thermo Fisher Scientific Inc.
